Remission with ursodeoxycholic acid of type 1 autoimmune hepatitis resistant to azathioprine and steroids

Gastroenterologie Clinique et Biologique

Volumn 29, Issue 11, 2005, Pages 1173-1176

  Duclos Vallée, Jean Charles ^a   Di Martino, Vincent ^b   Cazier, Alain ^c   Ballot, Eric ^d   Johanet, Catherine ^d   Yamamoto, Ana Maria ^e   Emile, Jean François ^a   Guettier, Catherine ^a   Coutarel, Pierre ^f   Cadranel, Jean François ^f  

^a HÔPITAL PAUL BROUSSE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CENTRE HOSPITALIER LAENNEC   (France)

^d HÔPITAL SAINT ANTOINE   (France)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f Centre Hospitalier de Creil   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; BIOCHEMISTRY; CASE REPORT; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; MONOTHERAPY; NAUSEA; RASH; REMISSION; TREATMENT OUTCOME;

EID: 30044448653     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(05)82185-2     Document Type: Article

References (26)

1. Czaja AJ. Autoimmune liver disease. In: Zakim D and Boyer T Eds. Hepatology. A textbook of liver disease. Vol II, 1259-92.
2. Krawitt EL. Autoimmune hepatitis. N Engl J Med 1996;334:897-9.
3. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in auto-immune hepatitis. N Engl J Med 1995;333:958-63.
4. Summerskill WHJ, Korman MG, Ammon HV, Baggentoss AH. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975;16:876-83.
5. Czaja AJ. Diagnosis, prognosis, and treatment of classical autoimmune chronic active hepatitis. In: Krawitt EL, Wiesner RH (Eds). Autoimmune liver disease. New York: Raven Press, 1991:143-66.
6. Alvarez F, Ciocca M, Canero-Velasco C, Ramonet M, de Davila MT, Cuarterolo M, et al. Short term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30: 222-7.
7. Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996;110:271-4.
8. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis resistant to or intolerant of azathioprine. J Hepatol 2000;33:371-5.
9. Van Thiel DH, Wright H, Caroll P, Abu-Elmagd K, Rodriguez-Rilo H, McMichael J, et al. Tacrolimus: a potential treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90:771-6.
10. Poupon RE, Poupon R, Balkau B, and the UDCA-PBC study group. Ursodiol for the long-term treatment of primary biliary cirrhosis. N Engl J Med 1994;330:1342-7.
11. Poupon RE, Bonnand AM, Chretien Y, Poupon R. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Hepatology 1999;29:1668-71.
12. Nakamura K, Yoneda M, Yokohama S, Tamori K, Sato Y, Aso K, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998;13:490-5.
13. Crosignani A, Battezzati PM, Setchell KD, Camisasca M, Bertolini E, Roda A, et al. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: A dose-response study. Hepatology 1991;13:339-44.
14. Czaja AJ. Autoimmune hepatitis. Current therapeutic concepts. Clin Immunother 1994;1:413-29.
15. Mima S, Sekiya C, Kanagawa H, Uchida T. Ursodeoxycholic acid (UDCA) therapy for autoimmune hepatitis. Int Hepatol Commun 1994;2:207-12.
16. Nakamura K, Yoneda M, Yokohama S, Tamori K, Sato Y, Aso K, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998;13:490-5.
17. Cadranel JF, Mathurin P. Prothrombin index decrease: a useful and reliable marker of of extensive fibrosis. Eur J Gastroenterol Hepatol 2002;14:1057-9.
18. Czaja AJ. Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 1998;28:360-5.
19. Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994;19:1149-56.
20. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-90.
21. Corpechot C, Carrat T, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000;32:1196-9.
22. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999;30:1381-6.
23. Czaja AJ, Strettell MDJ, Thomson LJ, Santrach PJ, Moore SB, Donaldson PT, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997;25:317-23.
24. Obermayer-Straub P, Sttassburg CP, Manns MP. Autoimmune hepatitis. J Hepatol 2000;32:181-97.
25. Calmus Y, Gano P, Rougier P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990;11:12-5.
26. Hillaire S, Boucher E, Calmus Y, Game P, Ballet F, Franco D, et al. Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes. Gastroenterology 1994;107:781-8.